Publications – Leucegene

2024

Spinella JF, Chagraoui J, Moison C, Lavallée VP, Boivin I, Gracias D, Lavallée S, Carpentier GR, Beliveau F, Hébert J, Sauvageau G. DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML. Leukemia. 2024 Mar;38(3):530-537. doi: 10.1038/s41375-023-02107-4.
Moison C, Gracias D, Schmitt J, Girard G, Spinella JF, Fortier S, Boivin I, Mendoza-Sanchez R, Thavonekham B, MacRae T, Mayotte N, Bonneil E, Wittman M, Carmichael J, Ruel R, Thibault P, Hébert J, Marinier A , Sauvageau G. SF3B1 mutations provide genetic vulnerability to copper ionophores in human Acute Myeloid Leukemia. Science Advances. 2024 Mar 22;10(12):eadl4018. Epub 2024 Mar 22. doi: 10.1126/sciadv.adl4018

2022

Krosl J, Bordeleau ME, Moison C, MacRae T, Boivin I, Mayotte N, Gracias D, Baccelli I, Lavallée VP, Bisaillon R, Lehnertz B, Mendoza-Sanchez R, Ruel R, Bertomeu T, Coulombe-Huntington J, Boucher G, Noronha N, Pabst C, Tyers M, Gendron P, Lemieux S, Barabé F, Marinier A, Hébert J, Sauvageau G. Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia. Blood Adv. 2022 Jan 25;6(2):509-514. doi: 10.1182/bloodadvances.2021006047.
Lisi V, Blanchard È, Vladovsky M, Audemard E, Ferghaly A, Lemieux S, Hébert J, Sauvageau G, Lavallée VP. Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia. Blood Adv. 2022 Jul 18: bloodadvances.2022007300. doi: 10.1182/bloodadvances.2022007300.
Moison C, Spinella JF, Chagraoui J, Lavallée VP, Lehnertz B, Thiollier C, Boivin I, Mayotte N, McRae T, Marinier A, Hébert J, Sauvageau G. HMGA2 expression defines a subset of AML with immature transcriptional signature and vulnerability to G2/M inhibition. Blood Adv. 2022 Jul 7: bloodadvances.2021005828. doi: 10.1182/bloodadvances.2021005828.

2020-2021

Lang M, Lemieux S, Hébert J, Sauvageau G, Zawati MH. Legal and Ethical Considerations for the Design and Use of Web Portals for Researchers, Clinicians, and Patients: Scoping Literature Review. Journal of Medical Internet Research. 2021. vol. 23:11. e26450.
Bisaillon R, Moison C, Thiollier C, Krosl J, Bordeleau ME, Lehnertz B, Lavallée VP, MacRae T, Mayotte N, Labelle C, Boucher G, Spinella JF, Boivin I, D’Angelo G, Lavallée S, Marinier A, Lemieux S, Hébert J, Sauvageau G. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia. 2020 Jan;34(1):63-74.doi: 10.1038/s41375-019-0485-x.
Simon L, Spinella JF, Yao CY, Lavallée VP, Boivin I, Boucher G, Audemard E, Bordeleau ME, Lemieux S, Hébert J, Sauvageau G. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. Blood. 2020 May 21;135(21):1882-1886. doi: 10.1182/blood.2019003357.

2019

Audemard EO, Gendron P, Feghaly A, Lavallée VP, Hébert J, Sauvageau G, Lemieux S. Targeted variant detection using unaligned RNA-Seq reads. Life Sci Alliance. 2019 Aug 19;2(4). pii: e201900336. doi: 10.26508/lsa.201900336.
Labelle C, Marinier A, Lemieux S. Enhancing the drug discovery process: Bayesian inference for the analysis and comparison of dose–response experiments. Bioinformatics,2019 Jul 15;35(14):i464-i473. doi: 10.1093/bioinformatics/btz335.
Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hébert J . Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting. Applied Health Economics and Health Policy. 07 August 2019. doi: 10.1007/s40258-019-00503-5.
Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella JF, Corneau S, Mayotte N, Girard S, Frechette M, Blouin-Chagnon V, Leveillé K, Boivin I, MacRae T, Krosl J, Thiollier C, Lavallée VP, Kanshin E, Bertomeu T, Coulombe-Huntington J, St-Denis C, Bordeleau ME, Boucher G, Roux PP, Lemieux S, Tyers M, Thibault P, Hébert J, Marinier A, Sauvageau G. Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. Cancer Cell. 2019 Jul 8;36(1):84-99.e8. doi: 10.1016/j.ccell.2019.06.003.
Moison C, Lavallée VP, Thiollier C, Lehnertz B, Boivin I, Mayotte N, Gareau Y, Fréchette M, Blouin-Chagnon V, Corneau S, Lavallée S, Lemieux S, Marinier A, Hébert J, Sauvageau G. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. Blood Adv.2019 Feb 26;3(4):552-563. doi: 10.1182/bloodadvances.2018028480.

2018

Marquis M#, Beaubois C#, Lavallée V-P, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, and Hébert J. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. #, equal contributions.
Audemard E, Gendron P, Lavallée VP, Hébert J, Sauvageau G, Lemieux S. Target variant detection in leukemia using unaligned RNA-Seq reads. Online on bioRxiv.
Lavallée VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A , Krosl J , Lemieux S , Marinier A , Pabst C, Rivard GE, Hebert J, Sauvageau G. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia 2018 Feb 23. doi: 10.1038/s41375-018-0069-1

2017

Lehnertz B, Zhang YW, Boivin I, Mayotte N, Tomellini E, Chagraoui J, Lavallée VP, Hébert J, Sauvageau G. H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1alterations. Blood 2017 Nov 16;130(20):2204-2214. doi: 10.1182/blood-2017-03-774653. Epub 2017 Aug 30.

Simon L, Lavallée VP, Bordeleau ME, Krosl J , Baccelli I, Boucher G , Lehnertz B, Chagraoui J, MacRae T, Ruel R , Chantigny YA , Lemieux S, Marinier A, Hébert J, Sauvageau G. Chemogenomic landscape of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity. Clinical Cancer Research 2017 Nov 15;23(22):6969-6981. doi: 10.1158/1078-0432.CCR-17-1259. Epub 2017 Aug 30.

Lemieux S, Sargeant T, Laperrière D, Ismail H, Boucher G, Rozendaal M, Lavallée VP, Ashton-Beaucage D, Wilhelm B, Hébert J, Hilton DJ, Mader S, Sauvageau G. MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets. Nucleic Acids Res. 2017 Jul 27;45(13):e122. doi: 10.1093/nar/gkx338.

Richard-Carpentier G, Sauvageau G. Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet? Cell Stem Cell. 2017 Mar 2;20(3):300-301. doi: 10.1016/j.stem.2017.02.010.

Baccelli I, Krosl J, Boucher G, Boivin I, Lavallée VP, Hébert J, Lemieux S, Marinier A, Sauvageau G. A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens. Blood Cancer J. 2017 Feb 17;7(2):e529. doi: 10.1038/bcj.2017.10.

2016

Maiga A, Lemieux S, Pabst C, Lavallée VP, Bouvier M, Sauvageau G, Hébert J. (2016). Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets. Blood Cancer J. 2016 Jun 3;6(6):e431. doi: 10.1038/bcj.2016.36.
Lavallée VP, Krosl J, Lemieux S, Boucher G, Gendron P, Pabst C, Boivin I, Marinier A, Guidos CJ, Meloche S, Hébert J, Sauvageau G. (2016). Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. Blood. 2016 Jun 16;127(24):3054-61. doi: 10.1182/blood-2016-03-705053. Epub 2016 Mar 31.
Lavallée VP, Lemieux S, Boucher G, Gendron P, Boivin I, Armstrong RN, Sauvageau G, Hébert J. (2016). RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. Blood. 2016 May 19;127(20):2498-501. doi: 10.1182/blood-2016-03-703868. Epub 2016 Mar 11.
Lavallée VP, Lemieux S, Boucher G, Gendron P, Boivin I, Girard S, Hébert J, Sauvageau G. (2016). Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations Leukemia. Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.19.
Pabst C, Bergeron A, Lavallée VP, Yeh J, Gendron P, Norddahl GL, Krosl J, Boivin I, Deneault E, Simard J, Imren S, Boucher G, Eppert K, Herold T, Bohlander SK, Humphries K, Lemieux S, Hébert J, Sauvageau G, Barabé F. (2016). GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood. 2016 Apr 21;127(16):2018-27. doi: 10.1182/blood-2015-11-683649. Epub 2016 Feb 1.
Shifman AR, Johnson RM, Wilhelm BT. (2016). Cascade: an RNA-seq visualization tool for cancer genomics. BMC Genomics. 2016 Jan 25;17(1):75. doi: 10.1186/s12864-016-2389-8.

2015

Kleiderman E, Avard D, Besso A, Ali-Khan S, Sauvageau G, Hébert J (2015). Disclosure of incidental findings in cancer genomic research: investigators’ perceptions on obligations and barriers. Clin. Genet. 88(4): 320-6.
Lavallée VP, Baccelli I, Krosl J, Wilhelm B, Barabé F, Gendron P, Boucher G, Lemieux S, Marinier A, Meloche S, Hébert J, Sauvageau G (2015). The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat. Genet. 47:1032-1037.
Lavallé VP, Gendron P, Lemieux S, D’Angelo G, Hébert J, Sauvageau G. (2015). EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood. 125(1): 140-3.

2014

Lehnertz B, Pabst C, Su L, Miller M, Liu F, Yi L, Zhang RG, Krosl J, Yung E, Kirschner J, Rosten P, Underhill TM, Jin J, Hébert J, Sauvageau G, Humphries RK, Rossi FM. (2014). The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 28(4): 317-27.
Pabst C, Krosl J, Fares I, Boucher G, Ruel R, Marinier A, Lemieux S, Hébert J, Sauvageau G. (2014). Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat. Methods. 11(4): 436-42.
Lavallée VP, Boivin I, Armstrong RN, Lemieux S, Hébert J, Sauvageau G. (2014, June). AML with EVI1 Rearrangements Are Characterized By Frequent SF3B1 And IKZF1 Mutations. 19th Congress of European Hematology Association (EHA), Milan, Italy. Published in Haematologica. 99(supp 1): 13.
Lavallée VP, Boivin I, Armstrong RN, Lemieux S, Gendron P, Hébert J, Sauvageau G. (2014, Aug). AML with EVI1 rearrangements are characterized by SF3B1 and IKZF1 mutations and distinct expression of MECOM isoforms. 43rd Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH), Montreal, Canada. Published in Exp. Hematol. 42(8): S44.
Lehnertz B, Boucher G, Mallard W, Gendron P, Hébert J, Lemieux S, Rinn J, Sauvageau G. (2014, Aug). Long non-coding RNA expression in normal and leukemic human blood samples: Towards the identification of novel biomarkers and hematopoietic regulators. 43rd Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH), Montreal, Canada. Published in Exp. Hematol. 42(8): S44.
Celton M, Forest A, Gosse G, Lemieux S, Hébert J, Sauvageau G, Wilhelm BT. (2014). Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia. Leukemia. 28(8): 1617-26.

2013

Macrae T, Sargeant T, Lemieux S, Hébert J, Deneault E, Sauvageau G. (2013). RNA-Seq Reveals Spliceosome and Proteasome Genes as Most Consistent Transcripts in Human Cancer Cells. PLoS One 8(9):e72884.
Lavallée VP, Gendron P, Boucher G, Arteau M, Wilhelm BT, Lemieux S, Hébert J, Sauvageau G. (2013, Nov). NGS-Based Detection Of Multiple RAS-Mutated Clones In MLL-Rearranged Leukemias Suggests Strong Oncogenic Collaboration. 55th Annual Meeting of the American Society of Hematology (ASH), New Orleans, USA. Published in Blood. 122(21): 744.
Sauvageau G, Pabst C, Lemieux S, Hébert J, Krosl J. (2013, Nov). Novel Targeting Strategies for Leukemia-Initiating Cells in Myeloid Neoplasms. 55th Annual Meeting of the American Society of Hematology (ASH), New Orleans, USA. Published in Blood. 122(21): SCI-27.
Black L, Avard D, Zawati MH, Knoppers BM, Hébert J, Sauvageau G. (2013). Funding considerations for the disclosure of genetic incidental findings in biobank research. Clin. Genet. 84(5):397-406.

2012